Star Imaging and Path Lab Ltd

Star Imaging and Path Lab Limited informed the BSE that its board approved the draft notice for the 22nd Annual General Meeting to be held on September 29, 2026, at 2:00 P.M. via video conferencing, and set the cut-off date for e-voting as September 24, 2026. The board also approved the Board’s Report and Management Discussion and Analysis Report for the financial year ended March 31, 2026, re-appointed M/s Sheetal & Company as Secretarial Auditor for the financial year 2026-27, and appointed Mr. Suraj Verma as Internal Auditor for the financial year 2026-27. Additionally, the board recommended the re-appointment of Ms. Neelam Ratra as Executive Director, who retires by rotation at the AGM.

Star Imaging & Path Lab will hold a meeting of the Board of Directors of the Company on 22 May 2026.

Star Imaging & Path Lab will hold a meeting of the Board of Directors of the Company on 13 November 2025.Powered by Capital Market - Live

The scrip was listed at Rs 142, matching the initial public offer (IPO) price. The counter hit a high of Rs 143 and a low of Rs 135.75. About 9.30 lakh shares of the company changed hands at the counter. Star Imaging and Path Lab's IPO was subscribed 5.04 times. The issue opened for bidding on 8 August 2025 and it closed on 12 August 2025. The price of the IPO was fixed between Rs 135-142 per share. The IPO comprised a fresh issue of 39,20,000 equity shares and an offer for sale (OFS) of 9,72,000 shares. The promoter shareholding in the company diluted to 71.92% post-IPO from 100% pre-IPO. The company intends to utilize the net proceeds for repayment/prepayment of certain borrowings, funding the capital expenditure towards installation of medical equipment in running facilities, to meet working capital requirements, and for general corporate purposes. Ahead of the IPO, Star Imaging and Path Lab, on 7 August 2025, raised Rs 18.51 crore from anchor investors. The board allotted 13.04 lakh shares at Rs 142 each to 11 anchor investors. Star Imaging and Path Lab operates a diagnostic testing network, NABL accredited, delivering pathology, radiology, cardiology, and neurology services in the Delhi (B2C, B2B & B2G model), Uttar Pradesh (B2G model), and Nasik (B2G model) regions of India. It offers a comprehensive range of diagnostic imaging services and clinical laboratory tests. As of March 31st, 2025, the company had 211 full-time employees, including executive directors. The company recorded revenue from operations of Rs 83.50 crore and a net profit of Rs 15.95 crore for the period ended 31 March 2025. Powered by Capital Market - Live